|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:weapon
cross-links DNA strands
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2008
gptkb:FDA
with sterile water
|
|
gptkbp:brand
|
Treanda
Bendeka
|
|
gptkbp:can_be_used_with
|
gptkb:obinutuzumab
gptkb:rituximab
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:class
|
nitrogen mustard
|
|
gptkbp:clinical_trial
|
Phase II
oncology
Phase III
|
|
gptkbp:community_service
|
not established
|
|
gptkbp:contraindication
|
severe liver disease
active infection
|
|
gptkbp:developed_by
|
gptkb:Cephalon,_Inc.
|
|
gptkbp:discovered_by
|
1960s
|
|
gptkbp:dosage_form
|
120 mg/m²
90 mg/m²
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bendamustine
|
|
gptkbp:indication
|
relapsed or refractory CLL
indolent B-cell non-Hodgkin lymphoma
|
|
gptkbp:ingredients
|
C16 H21 Cl2 N3 O2
|
|
gptkbp:interacts_with
|
live vaccines
other chemotherapy agents
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
renal function
complete blood count
|
|
gptkbp:is_used_for
|
treatment of chronic lymphocytic leukemia
treatment of non-Hodgkin lymphoma
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research
|
clinical trials
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
peripheral neuropathy
infusion reactions
low blood cell counts
tumor lysis syndrome
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:targets
|
gptkb:DJ
|
|
gptkbp:bfsParent
|
gptkb:obinutuzumab
|
|
gptkbp:bfsLayer
|
5
|